Reports
Sale
Pericarditis Market Size, Share, Trends, Growth, Report: By Diagnostic Method: Electrocardiogram (ECG), Echocardiogram, Computerized Tomography, X Ray, Others; By Drug Type: Nonsteroidal anti-inflammatory Drugs (NSAIDs), Others; By End User; By Distribution Channels; Regional Analysis; Supplier Landscape; 2024-2032
Pericarditis Market Outlook
The pericarditis market size was valued at USD 2.44 billion in 2023, driven by the rising prevalence of pericarditis across the 8 major markets. The market is expected to grow at a CAGR of 5.24% during the forecast period of 2024-2032, with the values likely to rise from USD 2.57 billion in 2024 to USD 3.87 billion by 2032.
Pericarditis Market Overview
Pericarditis is characterized by the inflammation of the pericardium (sac surrounding the heart) caused by various disorders such as myocardial infarction, infection, metabolic disorders, and tumors. Pericarditis is the most common pericardial disease, leading to 5.4-26 hospitalizations per 100,000 individuals annually in the United States. Recurrent pericarditis occurs in 30% of patients having acute pericarditis, with treatment lasting up to 7 years. The rising prevalence of the disease is expected to augment the market size in the forecast period.
The surge in approvals from health regulatory agencies also drives the pericarditis market growth. In February 2024 , the United States Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to a small molecule drug candidate called CardiolRx™ to treat pericarditis. Developed by Cardiol Therapeutics Inc., a clinical-stage life sciences company in the United States, the drug candidate is undergoing Phase II clinical trials for recurrent pericarditis and acute myocarditis.
The emergence of novel therapies to treat the condition and address a wider section of patients is expected to fuel the market demand in coming years. Increased research and development initiatives along with investments made by the key players is projected to boost the market size. Heightened awareness of heart health among patients through campaigns and trends is another significant factor contributing to the increasing market size.
Pericarditis Market Trends
| Key Trends | Description |
| Rising Prevalence of Pericarditis | Pericarditis is increasingly prevalent, leading to a significant number of hospitalizations annually in the United States. Surge in cardiovascular issues, owing to fast paced, and sedentary lifestyles among individuals is a notable market trend. |
| Emergence of Novel Therapies | Innovative therapies are being developed and tested in clinical trials for the treatment of pericarditis. The introduction of novel treatment options is anticipated to meet the growing demand for effective management of the condition. |
| Increased Research and Development Investments | Key players in the healthcare industry are investing significantly in research and development activities aimed at advancing the understanding and treatment of pericarditis. |
| Heightened Awareness of Heart Health Among Patients | Growing awareness of heart health and cardiovascular diseases among patients is leading to early detection and diagnosis of pericarditis. This increased awareness supports the demand for pericarditis treatments. |
Pericarditis Market Segmentation
- Market Breakup by Diagnostic Method
- Electrocardiogram (ECG)
- Echocardiogram
- Computerized Tomography
- X-Ray
- Others
In terms of diagnostic methods, the market is segmented into electrocardiogram (ECG), echocardiogram, computerized tomography (CT), and X-ray, among others. This segmentation ensures diagnosis and evaluation of pericarditis to facilitate appropriate treatment interventions.
Market Breakup by Drug Type
- Nonsteroidal anti-inflammatory drugs (NSAIDs)
- Colchicine
- Others
Based on the drug type, the market is segmented into nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, and others. NSAIDs are used to reduce inflammation and relieve pain associated with pericarditis. Colchicine has been effective in preventing recurrent pericarditis episodes.
Market Breakup by End User
- Hospitals & Clinics
- Medical Institutes and Research Laboratories
- Others
Based on end users, the pericarditis market share is segmented hospitals and clinics, as well as medical institutes and research laboratories, among others.
Market Breakup by Distribution Channels
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Major distribution channels of the market include hospital pharmacies, retail pharmacies, online pharmacies, and others. Increasing digitization has led to increased preference for online pharmacies amongst patients.
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
The market report includes 8 major markets projected to show significant growth in the forecast period. The segmentation based on the region covers the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. North America holds a high market value which can be attributed to the rising geriatric population base in the region. In addition, the presence of an advanced healthcare system and the increased prevalence of cardiovascular diseases are anticipated to propel the market growth.
Pericarditis Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Kiniksa Pharmaceuticals
- Pfizer Inc.
- Bayer AG
- AstraZeneca Plc
- Sanofi
- Johnson and Johnson Services, Inc.
- Merck & Co., Inc.
- Allergan Plc.
- Novartis AG
- Perkin Elmer Inc.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Diagnostic Method |
|
| Breakup by Drug Type |
|
| Breakup by End User |
|
| Breakup by Distribution Channels |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
Key Queries Solved in the Pericarditis Market Report
- What shifts and developments will shape the market landscape in the forecast period?
- What are the major drivers and challenges in the market?
- What are the prevailing trends and developments in the market?
- Which country is poised to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- What is the epidemiology, incidence and prevalence of pericarditis?
- How do factors such as the rising prevalence of pericarditis impact the pericarditis market size?
- What is the growth trajectory of the market by drug type?
- Which drug type holds the largest market share in the pericarditis market?
- What are the emerging therapeutic approaches and pipeline candidates in development for pericarditis management?
- What are the latest advancements in pericarditis drug research and development?
- What are the major drug approvals to manage pericarditis during the historical period?
- Which segment has the major impact on the market size?
- What investments and funding are driving research and development in the market?
- What are the key strategies adopted by leading pharmaceutical companies to gain market share?
- How are partnerships, collaborations, and mergers & acquisitions shaping the market dynamics?
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Pericarditis Market Overview – 8 Major Market
3.1 Pericarditis Market Historical Value (2017-2023)
3.2 Pericarditis Market Forecast Value (2024-2032)
4 Pericarditis Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Pericarditis Epidemiology Analysis – 8 Major Markets
6.1 8MM Epidemiology Scenario Overview (2017-2032)
6.2 United States Pericarditis Epidemiology Forecast (2017-2032)
6.3 EU-4 and United Kingdom Pericarditis Epidemiology Forecast (2017-2032)
6.3.1 Germany Pericarditis Epidemiology Forecast (2017-2032)
6.3.2 France Pericarditis Epidemiology Forecast (2017-2032)
6.3.3 Italy Pericarditis Epidemiology Forecast (2017-2032)
6.3.4 Spain Pericarditis Epidemiology Forecast (2017-2032)
6.3.5 United Kingdom Pericarditis Epidemiology Forecast (2017-2032)
6.4 Japan Pericarditis Epidemiology Forecast (2017-2032)
6.5 India Pericarditis Epidemiology Forecast (2017-2032)
7 Pericarditis Market Landscape – 8 Major Markets
7.1 Pericarditis: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Pericarditis Product Landscape
7.2.1 Analysis by Drug Type
7.2.2 Analysis by Diagnostic Method
7.2.3 Analysis by Distribution Channel
8 Pericarditis Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Pericarditis Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Pericarditis Market Segmentation – 8 Major Market
11.1 Pericarditis Market (2017-2032) by Diagnostic Method
11.1.1 Market Overview
11.1.2 Electrocardiogram (ECG)
11.1.3 Echocardiogram
11.1.4 Computerized Tomography
11.1.5 X Ray
11.1.6 Others
11.2 Pericarditis Market (2017-2032) by Drug Type
11.2.1 Market Overview
11.2.2 Nonsteroidal anti-inflammatory drugs (NSAIDs)
11.2.3 Colchicine
11.2.4 Others
11.3 Pericarditis Market (2017-2032) by End User
11.3.1 Market Overview
11.3.2 Hospitals & Clinics
11.3.3 Medical Institutes and Research Laboratories
11.3.4 Others
11.4 Pericarditis Market (2017-2032) by Distribution Channels
11.4.1 Market Overview
11.4.2 Hospital Pharmacy
11.4.3 Retail Pharmacy
11.4.4 Online Pharmacy
11.4.5 Others
11.5 Pericarditis Market (2017-2032) by Region
11.5.1 Market Overview
11.5.2 United States
11.5.3 EU-4 and the United Kingdom
11.5.3.1 Germany
11.5.3.2 France
11.5.3.3 Italy
11.5.3.4 Spain
11.5.3.5 United Kingdom
11.5.4 Japan
11.5.5 India
12 United States Pericarditis Market (2017-2032)
12.1 United States Pericarditis Market Historical Value (2017-2023)
12.2 United States Pericarditis Market Forecast Value (2024-2032)
12.3 United States Pericarditis Market (2017-2032) by Diagnostic Type
12.3.1 Market Overview
12.3.2 Electrocardiogram (ECG)
12.3.3 Echocardiogram
12.3.4 Computerized Tomography
12.3.5 X Ray
12.3.6 Others
12.4 United States Pericarditis Market (2017-2032) by Drug Type
12.4.1 Market Overview
12.4.2 Nonsteroidal anti-inflammatory drugs (NSAIDs)
12.4.3 Colchicine
12.4.4 Others
13 EU-4 and United Kingdom Pericarditis Market (2017-2032)
13.1 EU-4 and United Kingdom Pericarditis Market Historical Value (2017-2023)
13.2 EU-4 and United Kingdom Pericarditis Market Forecast Value (2024-2032)
13.3 EU-4 and United Kingdom Pericarditis Market (2017-2032) by Diagnostic Type
13.3.1 Market Overview
13.3.2 Electrocardiogram (ECG)
13.3.3 Echocardiogram
13.3.4 Computerized Tomography
13.3.5 X Ray
13.3.6 Others
13.4 EU-4 and United Kingdom Pericarditis Market (2017-2032) by Drug Type
13.4.1 Market Overview
13.4.2 Nonsteroidal anti-inflammatory drugs (NSAIDs)
13.4.3 Colchicine
13.4.4 Others
14 Japan Pericarditis Market
14.1 Japan Pericarditis Market Historical Value (2017-2023)
14.2 Japan Pericarditis Market Forecast Value (2024-2032)
14.3 Japan Pericarditis Market (2017-2032) by Diagnostic Type
14.3.1 Market Overview
14.3.2 Electrocardiogram (ECG)
14.3.3 Echocardiogram
14.3.4 Computerized Tomography
14.3.5 X Ray
14.3.6 Others
14.4 Japan Pericarditis Market (2017-2032) by Drug Type
14.4.1 Market Overview
14.4.2 Nonsteroidal anti-inflammatory drugs (NSAIDs)
14.4.3 Colchicine
14.4.4 Others
15 India Pericarditis Market
15.1 India Pericarditis Market (2017-2032) Historical Value (2017-2023)
15.2 India Pericarditis Market (2017-2032) Forecast Value (2024-2032)
15.3 India Pericarditis Market (2017-2032) by Diagnostic Type
15.3.1 Market Overview
15.3.2 Electrocardiogram (ECG)
15.3.3 Echocardiogram
15.3.4 Computerized Tomography
15.3.5 X Ray
15.3.6 Others
15.4 India Pericarditis Market (2017-2032) by Drug Type
15.4.1 Market Overview
15.4.2 Nonsteroidal anti-inflammatory drugs (NSAIDs)
15.4.3 Colchicine
15.4.4 Others
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 JAPAN PMDA
16.1.4 India CDSCO
17 Patent Analysis
17.1 Analysis by Type of Patent
17.2 Analysis by Publication year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by NIH Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding and Investment Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnerships and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Supplier Landscape
22.1 Kiniksa Pharmaceuticals
22.1.1 Financial Analysis
22.1.2 Product Portfolio
22.1.3 Demographic Reach and Achievements
22.1.4 Mergers and Acquisitions
22.1.5 Certifications
22.2 Pfizer Inc.
22.2.1 Financial Analysis
22.2.2 Product Portfolio
22.2.3 Demographic Reach and Achievements
22.2.4 Mergers and Acquisitions
22.2.5 Certifications
22.3 Bayer AG
22.3.1 Financial Analysis
22.3.2 Product Portfolio
22.3.3 Demographic Reach and Achievements
22.3.4 Mergers and Acquisitions
22.3.5 Certifications
22.4 AstraZeneca Plc
22.4.1 Financial Analysis
22.4.2 Product Portfolio
22.4.3 Demographic Reach and Achievements
22.4.4 Mergers and Acquisitions
22.4.5 Certifications
22.5 Sanofi
22.5.1 Financial Analysis
22.5.2 Product Portfolio
22.5.3 Demographic Reach and Achievements
22.5.4 Mergers and Acquisitions
22.5.5 Certifications
22.6 Johnson and Johnson Services, Inc.
22.6.1 Financial Analysis
22.6.2 Product Portfolio
22.6.3 Demographic Reach and Achievements
22.6.4 Mergers and Acquisitions
22.6.5 Certifications
22.7 Merck & Co., Inc.
22.7.1 Financial Analysis
22.7.2 Product Portfolio
22.7.3 Demographic Reach and Achievements
22.7.4 Mergers and Acquisitions
22.7.5 Certifications
22.8 Allergan Plc.
22.8.1 Financial Analysis
22.8.2 Product Portfolio
22.8.3 Demographic Reach and Achievements
22.8.4 Mergers and Acquisitions
22.8.5 Certifications
22.9 Novartis AG
22.9.1 Financial Analysis
22.9.2 Product Portfolio
22.9.3 Demographic Reach and Achievements
22.9.4 Mergers and Acquisitions
22.9.5 Certifications
22.10 Perkin Elmer Inc.
22.10.1 Financial Analysis
22.10.2 Product Portfolio
22.10.3 Demographic Reach and Achievements
22.10.4 Mergers and Acquisitions
22.10.5 Certifications
List not exhaustive
23 Pericarditis Market- Distribution Model (Additional Insight)
23.1 Overview
23.2 Potential Distributors
23.3 Key Parameters for Distribution Partner Assessment
24 Key Opinion Leaders (KOL) Insights (Additional Insight)
25 Company Competitiveness Analysis (Additional Insight)
25.1 Very Small Companies
25.2 Small Companies
25.3 Mid-Sized Companies
25.4 Large Companies
25.5 Very Large Companies
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 2.44 billion in 2023 driven by the rising prevalence of pericarditis across the 8 major markets.
The market is anticipated to grow at a CAGR of 5.24% during the forecast period of 2024-2032, likely to reach a market value of USD 3.87 billion by 2032.
The rise in cardiovascular diseases and growing awareness surrounding heart health are fuelling the demand for the market.
One of the significant trends in the market is the surge in drug approvals from health regulatory agencies such as the FDA. In February 2024, the United States FDA granted Orphan Drug Designation (ODD) to Cardiol Therapeutics' CardiolRx™, a small molecule drug candidate developed to treat pericarditis.
Based on the diagnostic methods, the market is segmented into electrocardiogram (ECG), echocardiogram, computerized tomography (CT), and X-ray.
Based on the drug type, the market is segmented into nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, and others.
Major end users of the market include hospitals and clinics, as well as medical institutes and research laboratories.
Major distribution channels of the market include hospital pharmacies, retail pharmacies, online pharmacies, and others.
The major regions of the market include the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India.
Key players involved in the market are Kiniksa Pharmaceuticals, Pfizer Inc., Bayer AG, AstraZeneca Plc, Sanofi, Johnson and Johnson Services, Inc., Merck & Co., Inc., Allergan Plc., Novartis AG, and Perkin Elmer Inc.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER